Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Marginal Zone Lymphoma
NCT06563505Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab, zanubrutinib in marginal zone lymphoma (MZL), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2024; status: recruiting.
02
Drugs
mosunetuzumabzanubrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06563505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563505.